Glucagon Market By Product Type (Injectable Glucagon, Nasal Glucagon) , By Application (Hypoglycemia, Diagnostic Aid) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) : Global Opportunity Analysis and Industry Forecast, 2024-2033
The glucagon market was valued at $0.3 billion in 2023, and is projected to reach $0.6 billion by 2033, growing at a CAGR of 6.4% from 2024 to 2033.
Glucagon is a peptide hormone produced by the alpha cells of the pancreas. It plays a critical role in glucose metabolism by increasing blood glucose levels when they drop too low, thus maintaining energy balance in the body. This hormone primarily acts on the liver, promoting glycogen breakdown (glycogenolysis) and stimulating the production of glucose from non-carbohydrate sources (gluconeogenesis). Glucagon works in opposition to insulin, which lowers blood glucose levels.
Alarming rise in global incidence of diabetes, particularly Type 1 diabetes, drives the demand for glucagon as it is a critical treatment for managing severe hypoglycemia. The International Diabetes Federation (2023) estimates that over 540 million adults live with diabetes globally, highlighting the importance of glucagon therapy. In addition, educational initiatives by healthcare organizations about hypoglycemia management have increased the adoption of glucagon products, particularly among diabetic patients at high risk for severe hypoglycemic episodes. Moreover, surge in geriatric population acts as the key driving force of the global market. With the aging global population, there is a growing number of individuals at risk for diabetes and related complications, driving the demand for glucagon products. A 2024 study published by the World Health Organization revealed that the number of aged individuals will increase from 1 billion in 2020 to 1.4 billion by 2030. Moreover, the number of individuals aging 80 years and older is estimated to reach 426 million by 2050. Furthermore, beyond its use in hypoglycemia, glucagon is increasingly employed in diagnostic imaging procedures (e.g., radiology and endoscopy) to relax the gastrointestinal tract, broadening its market scope. However, high cost of glucagon therapies, especially for newer formulations such as nasal glucagon, can be a significant barrier to access for patients, particularly in low-income regions or for those without sufficient healthcare coverage. The use of glucagon, especially in emergency settings, typically requires guidance from healthcare professionals for proper administration, which can further limit its use in situations where immediate access to medical help is unavailable. On the contrary, innovations such as prefilled syringes, auto-injectors, and nasal glucagon formulations enhance the ease of administration, making glucagon therapy more accessible and user-friendly for patients and caregivers. Such developments are anticipated to open new avenues for the expansion of the global market during the forecast period.
The global glucagon industry is segmented into type, application, distribution channel, and region. On the basis of type, the market is categorized into injectable glucagon and nasal glucagon. As per application, it is segregated into hypoglycemia and diagnostic aid. Depending on distribution channel, it is fragmented into hospital pharmacies, retail pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
By type, the injectable glucagon segment is expected to dominate the market from 2024 to 2033.
On the basis of application, the hypoglycemia segment is anticipated to exhibit the growth of the global market during the forecast period.
Depending on distribution channel, the hospital pharmacies segment is projected to grow at a notable pace throughout the forecast period.
Region wise, the glucagon market is likely to show strong growth in North America.
Competition Analysis
The major players operating in the global glucagon market include Novo Nordisk A/S, Fresenius SE & Co. KGaA, Amphastar Pharmaceuticals, Inc., Xeris Biopharma Holdings, Inc., ILS Inc, United Biotech (P) Limited, Zealand Pharma A/S, Taj Pharmaceuticals Limited, Eli Lilly and Company, and Pfizer Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.
Key Market Segments
By Product Type
Injectable Glucagon
Nasal Glucagon
By Application
Hypoglycemia
Diagnostic Aid
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
U.S.
Canada
Mexico
Europe
France
Germany
Italy
Spain
UK
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Saudi Arabia
Rest of LAMEA
Key Market Players
Novo Nordisk A/S
Fresenius SE & Co. KGaA
Amphastar Pharmaceuticals, Inc.
Xeris Biopharma Holdings, Inc.
ILS Inc
United Biotech (P) Limited
Zealand Pharma A/S
Taj Pharmaceuticals Limited
Eli Lilly and Company.
Pfizer Inc.
- CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
- CHAPTER 4: GLUCAGON MARKET, BY PRODUCT TYPE
- 4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Product Type
- 4.2. Injectable Glucagon
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Nasal Glucagon
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
- CHAPTER 5: GLUCAGON MARKET, BY APPLICATION
- 5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Application
- 5.2. Hypoglycemia
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
- 5.3. Diagnostic Aid
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
- CHAPTER 6: GLUCAGON MARKET, BY DISTRIBUTION CHANNEL
- 6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Distribution Channel
- 6.2. Hospital Pharmacies
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
- 6.3. Retail Pharmacies
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
- 6.4. Online Pharmacies
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country
- CHAPTER 7: GLUCAGON MARKET, BY REGION
- 7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Region
- 7.2. North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Product Type
- 7.2.3. Market Size and Forecast, By Application
- 7.2.4. Market Size and Forecast, By Distribution Channel
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. U.S. Glucagon Market
- 7.2.6.1. Market Size and Forecast, By Product Type
- 7.2.6.2. Market Size and Forecast, By Application
- 7.2.6.3. Market Size and Forecast, By Distribution Channel
- 7.2.7. Canada Glucagon Market
- 7.2.7.1. Market Size and Forecast, By Product Type
- 7.2.7.2. Market Size and Forecast, By Application
- 7.2.7.3. Market Size and Forecast, By Distribution Channel
- 7.2.8. Mexico Glucagon Market
- 7.2.8.1. Market Size and Forecast, By Product Type
- 7.2.8.2. Market Size and Forecast, By Application
- 7.2.8.3. Market Size and Forecast, By Distribution Channel
- 7.3. Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Product Type
- 7.3.3. Market Size and Forecast, By Application
- 7.3.4. Market Size and Forecast, By Distribution Channel
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. France Glucagon Market
- 7.3.6.1. Market Size and Forecast, By Product Type
- 7.3.6.2. Market Size and Forecast, By Application
- 7.3.6.3. Market Size and Forecast, By Distribution Channel
- 7.3.7. Germany Glucagon Market
- 7.3.7.1. Market Size and Forecast, By Product Type
- 7.3.7.2. Market Size and Forecast, By Application
- 7.3.7.3. Market Size and Forecast, By Distribution Channel
- 7.3.8. Italy Glucagon Market
- 7.3.8.1. Market Size and Forecast, By Product Type
- 7.3.8.2. Market Size and Forecast, By Application
- 7.3.8.3. Market Size and Forecast, By Distribution Channel
- 7.3.9. Spain Glucagon Market
- 7.3.9.1. Market Size and Forecast, By Product Type
- 7.3.9.2. Market Size and Forecast, By Application
- 7.3.9.3. Market Size and Forecast, By Distribution Channel
- 7.3.10. UK Glucagon Market
- 7.3.10.1. Market Size and Forecast, By Product Type
- 7.3.10.2. Market Size and Forecast, By Application
- 7.3.10.3. Market Size and Forecast, By Distribution Channel
- 7.3.11. Rest Of Europe Glucagon Market
- 7.3.11.1. Market Size and Forecast, By Product Type
- 7.3.11.2. Market Size and Forecast, By Application
- 7.3.11.3. Market Size and Forecast, By Distribution Channel
- 7.4. Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Product Type
- 7.4.3. Market Size and Forecast, By Application
- 7.4.4. Market Size and Forecast, By Distribution Channel
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. China Glucagon Market
- 7.4.6.1. Market Size and Forecast, By Product Type
- 7.4.6.2. Market Size and Forecast, By Application
- 7.4.6.3. Market Size and Forecast, By Distribution Channel
- 7.4.7. Japan Glucagon Market
- 7.4.7.1. Market Size and Forecast, By Product Type
- 7.4.7.2. Market Size and Forecast, By Application
- 7.4.7.3. Market Size and Forecast, By Distribution Channel
- 7.4.8. India Glucagon Market
- 7.4.8.1. Market Size and Forecast, By Product Type
- 7.4.8.2. Market Size and Forecast, By Application
- 7.4.8.3. Market Size and Forecast, By Distribution Channel
- 7.4.9. South Korea Glucagon Market
- 7.4.9.1. Market Size and Forecast, By Product Type
- 7.4.9.2. Market Size and Forecast, By Application
- 7.4.9.3. Market Size and Forecast, By Distribution Channel
- 7.4.10. Australia Glucagon Market
- 7.4.10.1. Market Size and Forecast, By Product Type
- 7.4.10.2. Market Size and Forecast, By Application
- 7.4.10.3. Market Size and Forecast, By Distribution Channel
- 7.4.11. Rest of Asia-Pacific Glucagon Market
- 7.4.11.1. Market Size and Forecast, By Product Type
- 7.4.11.2. Market Size and Forecast, By Application
- 7.4.11.3. Market Size and Forecast, By Distribution Channel
- 7.5. LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Product Type
- 7.5.3. Market Size and Forecast, By Application
- 7.5.4. Market Size and Forecast, By Distribution Channel
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Glucagon Market
- 7.5.6.1. Market Size and Forecast, By Product Type
- 7.5.6.2. Market Size and Forecast, By Application
- 7.5.6.3. Market Size and Forecast, By Distribution Channel
- 7.5.7. South Africa Glucagon Market
- 7.5.7.1. Market Size and Forecast, By Product Type
- 7.5.7.2. Market Size and Forecast, By Application
- 7.5.7.3. Market Size and Forecast, By Distribution Channel
- 7.5.8. Saudi Arabia Glucagon Market
- 7.5.8.1. Market Size and Forecast, By Product Type
- 7.5.8.2. Market Size and Forecast, By Application
- 7.5.8.3. Market Size and Forecast, By Distribution Channel
- 7.5.9. Rest of LAMEA Glucagon Market
- 7.5.9.1. Market Size and Forecast, By Product Type
- 7.5.9.2. Market Size and Forecast, By Application
- 7.5.9.3. Market Size and Forecast, By Distribution Channel
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top Winning Strategies
- 8.3. Product Mapping Of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top Player Positioning, 2023
- CHAPTER 9: COMPANY PROFILES
- 9.1. Novo Nordisk A/S
- 9.1.1. Company Overview
- 9.1.2. Key Executives
- 9.1.3. Company Snapshot
- 9.1.4. Operating Business Segments
- 9.1.5. Product Portfolio
- 9.1.6. Business Performance
- 9.1.7. Key Strategic Moves and Developments
- 9.2. Fresenius SE And Co. KGaA
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Operating Business Segments
- 9.2.5. Product Portfolio
- 9.2.6. Business Performance
- 9.2.7. Key Strategic Moves and Developments
- 9.3. Amphastar Pharmaceuticals, Inc.
- 9.3.1. Company Overview
- 9.3.2. Key Executives
- 9.3.3. Company Snapshot
- 9.3.4. Operating Business Segments
- 9.3.5. Product Portfolio
- 9.3.6. Business Performance
- 9.3.7. Key Strategic Moves and Developments
- 9.4. Xeris Biopharma Holdings, Inc.
- 9.4.1. Company Overview
- 9.4.2. Key Executives
- 9.4.3. Company Snapshot
- 9.4.4. Operating Business Segments
- 9.4.5. Product Portfolio
- 9.4.6. Business Performance
- 9.4.7. Key Strategic Moves and Developments
- 9.5. ILS Inc
- 9.5.1. Company Overview
- 9.5.2. Key Executives
- 9.5.3. Company Snapshot
- 9.5.4. Operating Business Segments
- 9.5.5. Product Portfolio
- 9.5.6. Business Performance
- 9.5.7. Key Strategic Moves and Developments
- 9.6. United Biotech (P) Limited
- 9.6.1. Company Overview
- 9.6.2. Key Executives
- 9.6.3. Company Snapshot
- 9.6.4. Operating Business Segments
- 9.6.5. Product Portfolio
- 9.6.6. Business Performance
- 9.6.7. Key Strategic Moves and Developments
- 9.7. Zealand Pharma A/S
- 9.7.1. Company Overview
- 9.7.2. Key Executives
- 9.7.3. Company Snapshot
- 9.7.4. Operating Business Segments
- 9.7.5. Product Portfolio
- 9.7.6. Business Performance
- 9.7.7. Key Strategic Moves and Developments
- 9.8. Taj Pharmaceuticals Limited
- 9.8.1. Company Overview
- 9.8.2. Key Executives
- 9.8.3. Company Snapshot
- 9.8.4. Operating Business Segments
- 9.8.5. Product Portfolio
- 9.8.6. Business Performance
- 9.8.7. Key Strategic Moves and Developments
- 9.9. Eli Lilly And Company.
- 9.9.1. Company Overview
- 9.9.2. Key Executives
- 9.9.3. Company Snapshot
- 9.9.4. Operating Business Segments
- 9.9.5. Product Portfolio
- 9.9.6. Business Performance
- 9.9.7. Key Strategic Moves and Developments
- 9.10. Pfizer Inc.
- 9.10.1. Company Overview
- 9.10.2. Key Executives
- 9.10.3. Company Snapshot
- 9.10.4. Operating Business Segments
- 9.10.5. Product Portfolio
- 9.10.6. Business Performance
- 9.10.7. Key Strategic Moves and Developments
- LIST OF TABLES
- TABLE 1. GLOBAL GLUCAGON MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 2. GLUCAGON MARKET FOR INJEC
- TABLE GLUCAGON, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 3. GLUCAGON MARKET FOR NASAL GLUCAGON, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 4. GLOBAL GLUCAGON MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 5. GLUCAGON MARKET FOR HYPOGLYCEMIA, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 6. GLUCAGON MARKET FOR DIAGNOSTIC AID, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 7. GLOBAL GLUCAGON MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 8. GLUCAGON MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 9. GLUCAGON MARKET FOR RETAIL PHARMACIES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 10. GLUCAGON MARKET FOR ONLINE PHARMACIES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 11. GLUCAGON MARKET, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 12. NORTH AMERICA GLUCAGON MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 13. NORTH AMERICA GLUCAGON MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 14. NORTH AMERICA GLUCAGON MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 15. NORTH AMERICA GLUCAGON MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 16. U.S. GLUCAGON MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 17. U.S. GLUCAGON MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 18. U.S. GLUCAGON MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 19. CANADA GLUCAGON MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 20. CANADA GLUCAGON MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 21. CANADA GLUCAGON MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 22. MEXICO GLUCAGON MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 23. MEXICO GLUCAGON MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 24. MEXICO GLUCAGON MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 25. EUROPE GLUCAGON MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 26. EUROPE GLUCAGON MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 27. EUROPE GLUCAGON MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 28. EUROPE GLUCAGON MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 29. FRANCE GLUCAGON MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 30. FRANCE GLUCAGON MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 31. FRANCE GLUCAGON MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 32. GERMANY GLUCAGON MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 33. GERMANY GLUCAGON MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 34. GERMANY GLUCAGON MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 35. ITALY GLUCAGON MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 36. ITALY GLUCAGON MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 37. ITALY GLUCAGON MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 38. SPAIN GLUCAGON MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 39. SPAIN GLUCAGON MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 40. SPAIN GLUCAGON MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 41. UK GLUCAGON MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 42. UK GLUCAGON MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 43. UK GLUCAGON MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 44. REST OF EUROPE GLUCAGON MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 45. REST OF EUROPE GLUCAGON MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 46. REST OF EUROPE GLUCAGON MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 47. ASIA-PACIFIC GLUCAGON MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 48. ASIA-PACIFIC GLUCAGON MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 49. ASIA-PACIFIC GLUCAGON MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 50. ASIA-PACIFIC GLUCAGON MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 51. CHINA GLUCAGON MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 52. CHINA GLUCAGON MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 53. CHINA GLUCAGON MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 54. JAPAN GLUCAGON MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 55. JAPAN GLUCAGON MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 56. JAPAN GLUCAGON MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 57. INDIA GLUCAGON MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 58. INDIA GLUCAGON MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 59. INDIA GLUCAGON MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 60. SOUTH KOREA GLUCAGON MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 61. SOUTH KOREA GLUCAGON MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 62. SOUTH KOREA GLUCAGON MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 63. AUSTRALIA GLUCAGON MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 64. AUSTRALIA GLUCAGON MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 65. AUSTRALIA GLUCAGON MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 66. REST OF ASIA-PACIFIC GLUCAGON MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 67. REST OF ASIA-PACIFIC GLUCAGON MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 68. REST OF ASIA-PACIFIC GLUCAGON MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 69. LAMEA GLUCAGON MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 70. LAMEA GLUCAGON MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 71. LAMEA GLUCAGON MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 72. LAMEA GLUCAGON MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 73. BRAZIL GLUCAGON MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 74. BRAZIL GLUCAGON MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 75. BRAZIL GLUCAGON MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 76. SOUTH AFRICA GLUCAGON MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 77. SOUTH AFRICA GLUCAGON MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 78. SOUTH AFRICA GLUCAGON MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 79. SAUDI ARABIA GLUCAGON MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 80. SAUDI ARABIA GLUCAGON MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 81. SAUDI ARABIA GLUCAGON MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 82. REST OF LAMEA GLUCAGON MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 83. REST OF LAMEA GLUCAGON MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 84. REST OF LAMEA GLUCAGON MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 85. NOVO NORDISK A/S: KEY EXECUTIVES
- TABLE 86. NOVO NORDISK A/S: COMPANY SNAPSHOT
- TABLE 87. NOVO NORDISK A/S: OPERATING SEGMENTS
- TABLE 88. NOVO NORDISK A/S: PRODUCT PORTFOLIO
- TABLE 89. NOVO NORDISK A/S: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 90. FRESENIUS SE AND CO. KGAA: KEY EXECUTIVES
- TABLE 91. FRESENIUS SE AND CO. KGAA: COMPANY SNAPSHOT
- TABLE 92. FRESENIUS SE AND CO. KGAA: OPERATING SEGMENTS
- TABLE 93. FRESENIUS SE AND CO. KGAA: PRODUCT PORTFOLIO
- TABLE 94. FRESENIUS SE AND CO. KGAA: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 95. AMPHASTAR PHARMACEUTICALS, INC.: KEY EXECUTIVES
- TABLE 96. AMPHASTAR PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
- TABLE 97. AMPHASTAR PHARMACEUTICALS, INC.: OPERATING SEGMENTS
- TABLE 98. AMPHASTAR PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
- TABLE 99. AMPHASTAR PHARMACEUTICALS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 100. XERIS BIOPHARMA HOLDINGS, INC.: KEY EXECUTIVES
- TABLE 101. XERIS BIOPHARMA HOLDINGS, INC.: COMPANY SNAPSHOT
- TABLE 102. XERIS BIOPHARMA HOLDINGS, INC.: OPERATING SEGMENTS
- TABLE 103. XERIS BIOPHARMA HOLDINGS, INC.: PRODUCT PORTFOLIO
- TABLE 104. XERIS BIOPHARMA HOLDINGS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 105. ILS INC: KEY EXECUTIVES
- TABLE 106. ILS INC: COMPANY SNAPSHOT
- TABLE 107. ILS INC: OPERATING SEGMENTS
- TABLE 108. ILS INC: PRODUCT PORTFOLIO
- TABLE 109. ILS INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 110. UNITED BIOTECH (P) LIMITED: KEY EXECUTIVES
- TABLE 111. UNITED BIOTECH (P) LIMITED: COMPANY SNAPSHOT
- TABLE 112. UNITED BIOTECH (P) LIMITED: OPERATING SEGMENTS
- TABLE 113. UNITED BIOTECH (P) LIMITED: PRODUCT PORTFOLIO
- TABLE 114. UNITED BIOTECH (P) LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 115. ZEALAND PHARMA A/S: KEY EXECUTIVES
- TABLE 116. ZEALAND PHARMA A/S: COMPANY SNAPSHOT
- TABLE 117. ZEALAND PHARMA A/S: OPERATING SEGMENTS
- TABLE 118. ZEALAND PHARMA A/S: PRODUCT PORTFOLIO
- TABLE 119. ZEALAND PHARMA A/S: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 120. TAJ PHARMACEUTICALS LIMITED: KEY EXECUTIVES
- TABLE 121. TAJ PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
- TABLE 122. TAJ PHARMACEUTICALS LIMITED: OPERATING SEGMENTS
- TABLE 123. TAJ PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
- TABLE 124. TAJ PHARMACEUTICALS LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 125. ELI LILLY AND COMPANY.: KEY EXECUTIVES
- TABLE 126. ELI LILLY AND COMPANY.: COMPANY SNAPSHOT
- TABLE 127. ELI LILLY AND COMPANY.: OPERATING SEGMENTS
- TABLE 128. ELI LILLY AND COMPANY.: PRODUCT PORTFOLIO
- TABLE 129. ELI LILLY AND COMPANY.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 130. PFIZER INC.: KEY EXECUTIVES
- TABLE 131. PFIZER INC.: COMPANY SNAPSHOT
- TABLE 132. PFIZER INC.: OPERATING SEGMENTS
- TABLE 133. PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 134. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- LIST OF FIGURES
- FIGURE 1. GLOBAL GLUCAGON MARKET, 2024 - 2033
- FIGURE 2. SEGMENTATION OF GLUCAGON MARKET, 2024 - 2033
- FIGURE 3. TOP INVESTMENT POCKET IN GLUCAGON MARKET
- FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 7. LOW THREAT OF SUBSTITUTION
- FIGURE 8. HIGH COMPETITIVE RIVALRY
- FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALGLUCAGON MARKET
- FIGURE 10. GLOBAL GLUCAGON MARKET SEGMENTATION, BY PRODUCT TYPE
- FIGURE 11. GLUCAGON MARKET FOR INJECTABLE GLUCAGON, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 12. GLUCAGON MARKET FOR NASAL GLUCAGON, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 13. GLOBAL GLUCAGON MARKET SEGMENTATION, BY APPLICATION
- FIGURE 14. GLUCAGON MARKET FOR HYPOGLYCEMIA, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 15. GLUCAGON MARKET FOR DIAGNOSTIC AID, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 16. GLOBAL GLUCAGON MARKET SEGMENTATION, BY DISTRIBUTION CHANNEL
- FIGURE 17. GLUCAGON MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 18. GLUCAGON MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 19. GLUCAGON MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 20. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
- FIGURE 21. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
- FIGURE 22. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
- FIGURE 23. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 24. COMPETITIVE DASHBOARD
- FIGURE 25. COMPETITIVE HEATMAP: GLUCAGON MARKET
- FIGURE 26. TOP PLAYER POSITIONING, 2023
- FIGURE 27. NOVO NORDISK A/S: NET SALES, 2021-2023 ($BILLION)
- FIGURE 28. NOVO NORDISK A/S: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 29. NOVO NORDISK A/S: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 30. FRESENIUS SE AND CO. KGAA: NET SALES, 2021-2023 ($BILLION)
- FIGURE 31. FRESENIUS SE AND CO. KGAA: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 32. FRESENIUS SE AND CO. KGAA: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 33. AMPHASTAR PHARMACEUTICALS, INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 34. AMPHASTAR PHARMACEUTICALS, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 35. AMPHASTAR PHARMACEUTICALS, INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 36. XERIS BIOPHARMA HOLDINGS, INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 37. XERIS BIOPHARMA HOLDINGS, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 38. XERIS BIOPHARMA HOLDINGS, INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 39. ILS INC: NET SALES, 2021-2023 ($BILLION)
- FIGURE 40. ILS INC: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 41. ILS INC: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 42. UNITED BIOTECH (P) LIMITED: NET SALES, 2021-2023 ($BILLION)
- FIGURE 43. UNITED BIOTECH (P) LIMITED: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 44. UNITED BIOTECH (P) LIMITED: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 45. ZEALAND PHARMA A/S: NET SALES, 2021-2023 ($BILLION)
- FIGURE 46. ZEALAND PHARMA A/S: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 47. ZEALAND PHARMA A/S: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 48. TAJ PHARMACEUTICALS LIMITED: NET SALES, 2021-2023 ($BILLION)
- FIGURE 49. TAJ PHARMACEUTICALS LIMITED: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 50. TAJ PHARMACEUTICALS LIMITED: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 51. ELI LILLY AND COMPANY.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 52. ELI LILLY AND COMPANY.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 53. ELI LILLY AND COMPANY.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 54. PFIZER INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 55. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 56. PFIZER INC.: REVENUE SHARE, BY REGION, 2023 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook